Literature DB >> 33328591

Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma.

Franck Morschhauser1, Martin J S Dyer2, Harriet S Walter2, Alexey V Danilov3, Loic Ysebaert4, Daniel James Hodson5, Christopher Fegan6, Simon A Rule7, John Radford8, Guillaume Cartron9, Krimo Bouabdallah10, Andrew John Davies11, Stephen Spurgeon12, Nishanthan Rajakumaraswamy13, Biao Li13, Rita Humeniuk13, Xi Huang13, Pankaj Bhargava13, Juliane M Jürgensmeier13, Gilles Salles14.   

Abstract

Entities:  

Year:  2020        PMID: 33328591     DOI: 10.1038/s41375-020-01108-x

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  4 in total

1.  Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring.

Authors:  Caitlin M Stewart; Laure Michaud; Karissa Whiting; Dana W Y Tsui; Connie Lee Batlevi; Reiko Nakajima; Chelsea Nichols; Stephanie De Frank; Paul A Hamlin; Matthew J Matasar; John F Gerecitano; Pamela Drullinsky; Audrey Hamilton; David Straus; Steven M Horwitz; Anita Kumar; Craig H Moskowitz; Alison Moskowitz; Andrew D Zelenetz; Jurgen Rademaker; Gilles Salles; Venkatraman Seshan; Heiko Schöder; Anas Younes
Journal:  Clin Cancer Res       Date:  2021-10-06       Impact factor: 13.801

2.  Semi-Mechanistic PK/PD Modeling and Simulation of Irreversible BTK Inhibition to Support Dose Selection of Tirabrutinib in Subjects with RA.

Authors:  Amy Meng; Rita Humeniuk; Juliane M Jürgensmeier; Chia-Hsiang Hsueh; Franziska Matzkies; Ethan Grant; Hoa Truong; Andrew N Billin; Helen Yu; Joy Feng; Ellen Kwan; Thomas Tarnowski; Cara H Nelson
Journal:  Clin Pharmacol Ther       Date:  2021-10-27       Impact factor: 6.903

Review 3.  Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features.

Authors:  Matt Shirley
Journal:  Target Oncol       Date:  2021-12-14       Impact factor: 4.493

4.  Dual BTK/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma.

Authors:  Elana Thieme; Tingting Liu; Nur Bruss; Carly Roleder; Vi Lam; Xiaoguang Wang; Tamilla Nechiporuk; Geoffrey Shouse; Olga V Danilova; Daniel Bottomly; Shannon K McWeeney; Jeffrey W Tyner; Stephen E Kurtz; Alexey V Danilov
Journal:  Cell Death Dis       Date:  2022-03-16       Impact factor: 8.469

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.